We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Despite facing legal costs associated with its attempt to terminate a merger agreement with Sun Pharmaceutical, Israeli drugmaker Taro Pharmaceutical has reported gross profit of about $91.5 million for the first half of the year.